Sunshine Biopharma (SBFM) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Sunshine Biopharma (SBFM) over the last 13 years, with Q3 2025 value amounting to -$883820.0.
- Sunshine Biopharma's Income from Continuing Operations rose 2621.32% to -$883820.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.0 million, marking a year-over-year decrease of 4180.64%. This contributed to the annual value of -$5.1 million for FY2024, which is 1393.84% down from last year.
- Per Sunshine Biopharma's latest filing, its Income from Continuing Operations stood at -$883820.0 for Q3 2025, which was up 2621.32% from -$1.8 million recorded in Q2 2025.
- In the past 5 years, Sunshine Biopharma's Income from Continuing Operations registered a high of $667116.0 during Q4 2021, and its lowest value of -$23.5 million during Q4 2022.
- Over the past 5 years, Sunshine Biopharma's median Income from Continuing Operations value was -$1.3 million (recorded in 2023), while the average stood at -$2.8 million.
- Examining YoY changes over the last 5 years, Sunshine Biopharma's Income from Continuing Operations showed a top increase of 16155.38% in 2021 and a maximum decrease of 646184.13% in 2021.
- Quarter analysis of 5 years shows Sunshine Biopharma's Income from Continuing Operations stood at $667116.0 in 2021, then tumbled by 3624.47% to -$23.5 million in 2022, then soared by 94.68% to -$1.3 million in 2023, then tumbled by 72.65% to -$2.2 million in 2024, then skyrocketed by 59.05% to -$883820.0 in 2025.
- Its last three reported values are -$883820.0 in Q3 2025, -$1.8 million for Q2 2025, and -$1.2 million during Q1 2025.